Yang Xiang to Adult
This is a "connection" page, showing publications Yang Xiang has written about Adult.
Connection Strength
0.877
-
Zhang Y, Guan Y, Xiao X, Xu S, Zhu S, Cao D, Yu M, Peng P, Wang J, Wang Y, Yin R, Guo J, Gao W, Li P, Bai J, Gong Y, Xia X, Yi X, Yang L, Xiang Y. Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer. BMC Cancer. 2024 Dec 22; 24(1):1565.
Score: 0.067
-
He SQ, Liu GY, Yu YH, Wang L, Zhang GY, Peng DS, Bei WX, Chen CL, Lv SH, Zhao ZY, Huang Y, Xiang YQ. Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study. Radiother Oncol. 2025 02; 203:110687.
Score: 0.067
-
He SQ, Liu GY, Yu YH, Wang L, Zhang GY, Peng DS, Bei WX, Chen CL, Lv SH, Zhao ZY, Huang Y, Xiang YQ. Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study. Oral Oncol. 2024 Dec; 159:107074.
Score: 0.066
-
Liu GY, Ye YF, Jiang YF, Chen GJ, Xia WX, Huang YS, Gao TS, Liu YM, Hou YT, Li JF, Liu JH, Lu N, Chen CL, Ke LR, Liang H, Bei WX, Li WZ, Dong SH, Liu Q, Xie C, Yao HR, Xiang YQ. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ. 2024 06 19; 385:e077890.
Score: 0.064
-
Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, Zhao J, Wan X, Yang J, Xiang Y. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1609-1617.
Score: 0.053
-
Xia WX, Lv X, Liang H, Liu GY, Sun R, Zeng Q, Li SW, Mo HY, Han F, Luo DH, Liu Q, Shi MY, Ye YF, Yang J, Ke LR, Qiang MY, Qiu WZ, Yu YH, Liu KY, Huang XJ, Li WZ, Lv SH, Cai ZC, Miao JJ, Guo L, Chen MY, Cao KJ, Wang L, Zhao C, Huang PY, Chen QY, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ. A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. Clin Cancer Res. 2021 08 01; 27(15):4186-4194.
Score: 0.052
-
Li WZ, Lv SH, Liu GY, Liang H, Guo X, Lv X, Liu KY, Qiang MY, Chen X, Gu SZ, Xie CQ, Xia WX, Xiang YQ. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):120-130.
Score: 0.049
-
Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS, Zhu XY, Giunta B, Tan J, Song WH, Zhou HD, Zhou XF, Wang YJ. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol. 2015 Oct; 130(4):487-99.
Score: 0.035
-
Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 Apr 10; 7(4):101029.
Score: 0.018
-
Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Bai YR, Wu SX, Ke LR, Chen X, Liang CX, Luo ZY, Xia Y, Deng Y, Miao JJ, Xia WX, Liang H, Zhao C, Xiang YQ, Guo X, Lv X. Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial. Nat Commun. 2026 02 10; 17(1).
Score: 0.018
-
Liu Q, Wei JN, Zhou JY, Zhang CR, Ke LR, Lu N, Deng Y, Kuang YW, Hua YC, Wang MW, Gong J, Dong SH, Wu L, Lv X, Xiang YQ, Guo X, Xia WX. Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma. Oral Oncol. 2026 Feb; 173:107825.
Score: 0.018
-
He SQ, Huang Y, Zhao ZY, Wen SQ, Lv SH, Wang L, Bei WX, Xiang YQ, Liu GY. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study. Br J Cancer. 2026 Feb; 134(4):598-607.
Score: 0.018
-
He SQ, Lv SH, Wen SQ, Wang L, Yu YH, Zhang GY, Peng DS, Bei WX, Chen CL, Zhao ZY, Huang Y, Xiang YQ, Liu GY. Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study. BMC Cancer. 2025 Dec 02; 25(1):1847.
Score: 0.018
-
He SQ, Lv SH, Wen SQ, Yu YH, Zhang GY, Peng DS, Bei WX, Chen CL, Zhao ZY, Huang Y, Xiang YQ, Liu GY. Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study. Radiother Oncol. 2025 12; 213:111160.
Score: 0.018
-
Xu C, Liang XY, Huang XQ, Jin F, Yang KY, Hu GY, Zhu XD, Wang Y, Huang Y, Zhang N, Hu DS, Guo L, Zou GR, Chen XZ, Xiao SW, Li JG, Shen LF, Li YY, Huang J, Long GX, Li L, Huang L, She LJ, Wu Y, Zeng WH, Qiang MY, Liu WX, Su Y, Tang LL, Xie FY, Han F, Lu LX, Xiang YQ, Mao YP, Li WF, Liu X, Yang Q, Zhou GQ, Guo R, Ouyang PY, Wang XH, Chen L, Liu LT, Lin L, Li JB, Lin AH, Zhao HY, Hong SB, Jie YS, Huang HL, Tang XH, Zeng YC, Yun JP, Zang SB, Du ZM, Ye ZL, Liu LZ, Tian L, Li HJ, Peng YL, Liu N, Li YQ, Liang YL, Wei HM, Chen YP, Zhang Y, Du XJ, Lv JW, Sun Y, Ma J. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. 2025 Sep 16; 334(11):973-983.
Score: 0.018
-
Guo SS, Li XY, Liu LT, Jia GD, Liu SL, Sun XS, Luo DH, Yang JH, Xie SY, Li YF, Lv X, Xiang YQ, Xia WX, Sun R, Liu Q, Li JB, Wang P, Yang Q, Wang L, Wen DX, Jin J, Lin JY, Mo HY, Guo L, Zhao C, Guo X, Chen QY, Tang LQ, Mai HQ. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Aug 01; 11(8):864-873.
Score: 0.017
-
Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V, Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025 Aug; 199:88-95.
Score: 0.017
-
Gui T, Cao D, Yang J, Wei Z, Xie J, Wang W, Xiang Y, Peng P. Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches. J Gynecol Oncol. 2025 07; 36(4):e53.
Score: 0.017
-
Wang WX, Wu YS, Qi LP, Wu AMS, Zhu YY, Gong WJ, Guo SS, Hua YJ, Luo DH, Chen QY, Xiang YQ, Zhang JX, Mai HQ, Li JB. Prevalence of mental disorders and their associations with age at diagnosis and time since diagnosis of nasopharyngeal cancer. Front Public Health. 2024; 12:1469001.
Score: 0.017
-
Feng Y, Cheng B, Zhan S, Liu H, Li J, Chen P, Wang Z, Huang X, Fu X, Ye W, Wang R, Wang Q, Xiang Y, Wang H, Zhu F, Zheng X, Fu W, Hu G, Chen Z, He J, Liang W. The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study. Eur J Nucl Med Mol Imaging. 2024 Sep; 51(11):3400-3416.
Score: 0.016
-
Yang HX, Zhou HY, Li Y, Cui YH, Xiang Y, Yuan RM, Lui SSY, Chan RCK. Decreased interoceptive accuracy in children with autism spectrum disorder and with comorbid attention deficit/hyperactivity disorder. Autism Res. 2022 04; 15(4):729-739.
Score: 0.014
-
Jiang F, Lin JK, Xiang Y, Xu ZF, Wan XR, Feng FZ, Ren T, Yang JJ, Zhao J. The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study. Eur J Cancer. 2022 01; 161:119-127.
Score: 0.014
-
Gao X, Yu H, Peng L, Gong X, Xiang Y, Jiang C, Zhou X. The mutuality of social emotions: How the victim's reactive attitude influences the transgressor's emotional responses. Neuroimage. 2021 12 01; 244:118631.
Score: 0.013
-
Zheng H, Gao Y, Guo H, Li L, Li Q, Cui H, Lin A, Sun L, Hu Y, Kang S, Duan W, Pan L, Wang S, Yang Y, Li Y, Kong W, Xiang Y, Tian X, Ling B, Ha C, Bai W. Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Mol Cancer Ther. 2021 09; 20(9):1735-1742.
Score: 0.013
-
Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 05; 22(5):716-726.
Score: 0.013
-
Yang J, Zhang H, Sun S, Wang X, Guan Y, Mi Q, Zeng W, Xiang H, Zhu H, Zou X, You Y, Xiang Y, Gao Q. Autophagy and Hsp70 activation alleviate oral epithelial cell death induced by food-derived hypertonicity. Cell Stress Chaperones. 2020 03; 25(2):253-264.
Score: 0.012
-
Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019 09; 119:87-96.
Score: 0.012
-
Li YM, Peng C, Zhang JG, Zhu W, Xu C, Lin Y, Fu XY, Tian Q, Zhang L, Xiang Y, Sheng V, Deng HW. Genetic risk factors identified in populations of European descent do not improve the prediction of osteoporotic fracture and bone mineral density in Chinese populations. Sci Rep. 2019 04 15; 9(1):6086.
Score: 0.011
-
Liu GY, Lv X, Wu YS, Mao MJ, Ye YF, Yu YH, Liang H, Yang J, Ke LR, Qiu WZ, Huang XJ, Li WZ, Guo X, Xiang YQ, Xia WX. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun (Lond). 2018 05 10; 38(1):21.
Score: 0.011
-
Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, Qi B, Tang QN, Wang P, Li XY, Li JB, Liu Q, Gao YH, Xie FY, Liu LT, Li Y, Liu SL, Xie HJ, Liang YJ, Sun XS, Yan JJ, Wu YS, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Lv X, Wang L, Xia WX, Zhao C, Cao KJ, Qian CN, Guo X, Hong MH, Nie ZQ, Chen QY, Mai HQ. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018 04; 19(4):461-473.
Score: 0.010
-
Qiu WZ, Ke LR, Xia WX, Yang J, Yu YH, Liang H, Huang XJ, Liu GY, Li WZ, Xiang YQ, Guo X, Lv X. A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. PLoS One. 2017; 12(8):e0182963.
Score: 0.010
-
Xie P, Yang JP, Cao Y, Peng LX, Zheng LS, Sun R, Meng DF, Wang MY, Mei Y, Qiang YY, Cao L, Xiang YQ, Luo DH, Yun JP, Huang BJ, Jia LJ, Qian CN. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target. Cell Death Dis. 2017 06 01; 8(6):e2834.
Score: 0.010
-
Ke LR, Xia WX, Qiu WZ, Huang XJ, Yu YH, Liang H, Liu GY, Xiang YQ, Guo X, Lv X. A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Oral Oncol. 2017 07; 70:7-13.
Score: 0.010
-
Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer. 2017 04; 75:14-23.
Score: 0.010
-
Liang H, Xiang YQ, Lv X, Xie CQ, Cao SM, Wang L, Qian CN, Yang J, Ye YF, Gan F, Ke LR, Yu YH, Liu GY, Qiu WZ, Huang XJ, Wen CH, You N, Wang XQ, Guo X, Xia WX. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. Eur J Cancer. 2017 03; 73:48-60.
Score: 0.010
-
Guo SS, Tang LQ, Chen QY, Zhang L, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Wang L, Lv X, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA =4000 copies/ml: a matched study. Oncotarget. 2016 May 17; 7(20):29739-48.
Score: 0.009
-
Guo SS, Tang LQ, Zhang L, Chen QY, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Wang L, Lv X, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer. 2015 Dec 16; 15:977.
Score: 0.009
-
Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ, Zeng MS. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2016 Jan; 108(1).
Score: 0.009
-
Ye YF, Xiang YQ, Fang F, Gao R, Zhang LF, Xie SH, Liu Z, Du JL, Chen SH, Hong MH, Qian CN, Ye W, Zeng YX, Liu Q, Cao SM. Hepatitis B virus infection and risk of nasopharyngeal carcinoma in southern China. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1766-73.
Score: 0.009
-
Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012 Oct; 48(10):1038-1044.
Score: 0.007